New hope for Australian leukaemia and lymphoma patients with key treatment option listed on PBS
A key new cancer treatment has just become more accessible for Australians fighting specific forms of leukaemia and lymphoma, thanks to the Morrison Government’s listing of Calquence® on the Pharmaceutical Benefits Scheme (PBS). On September 1, Calquence® (acalabrutinib) will be listed on the PBS for the first time for the treatment of chronic lymphocytic leukaemia…